MARKET

AUTL

AUTL

AUTOLUS THERAPEUTICS PLC
NASDAQ
2.175
-0.155
-6.65%
Opening 11:42 08/12 EDT
OPEN
2.340
PREV CLOSE
2.330
HIGH
2.410
LOW
2.150
VOLUME
1.74M
TURNOVER
--
52 WEEK HIGH
2.520
52 WEEK LOW
1.175
MARKET CAP
578.90M
P/E (TTM)
-2.0033
1D
5D
1M
3M
1Y
5Y
1D
Wells Fargo Gives a Buy Rating to Autolus Therapeutics (AUTL)
TipRanks · 7h ago
Autolus Q2 Net Loss Narrows As AUCATZYL Sales Surge 119%; CARLYSLE Data Expected By Year-End
NASDAQ · 9h ago
Analysts Offer Insights on Healthcare Companies: Odyssey Therapeutics, Inc. (ODTX), Metagenomi, Inc. (MGX) and Autolus Therapeutics (AUTL)
TipRanks · 10h ago
Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL) and Cronos Group (CRON)
TipRanks · 23h ago
Gil Blum Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target on Margin Gains and Strong Aucatzyl Trajectory
TipRanks · 1d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 1d ago
Autolus Lifts 2026 Guidance as AUCATZYL Sales Surge
TipRanks · 1d ago
Autolus Therapeutics' AUCATZYL Q2 Revenue Surges 119%; Boosts FY26 Outlook
NASDAQ · 1d ago
More
About AUTL
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.

Webull offers Autolus Therapeutics PLC (ADR) stock information, including NASDAQ: AUTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUTL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AUTL stock methods without spending real money on the virtual paper trading platform.